The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Abstract
The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long-standing goal. Genetic studies in humans and mice have shown that the secreted protein sclerostin is a key negative regulator of bone formation, although the magnitude and extent of sclerostin's role in the control of bone formation in the aging skeleton is still unclear. To study this unexplored area of sclerostin biology and to assess the pharmacologic effects of sclerostin inhibition, we used a cell culture model of bone formation to identify a sclerostin neutralizing monoclonal antibody (Scl-AbII) for testing in an aged ovariectomized rat model of postmenopausal osteoporosis. Six-month-old female rats were ovariectomized and left untreated for 1 yr to allow for significant estrogen deficiency-induced bone loss, at which point Scl-AbII was administered for 5 wk. Scl-AbII treatment in these animals had robust anabolic effects, with marked increases in bone formation on trabecular, periosteal, endocortical, and intracortical surfaces. This not only resulted in complete reversal, at several skeletal sites, of the 1 yr of estrogen deficiency-induced bone loss, but also further increased bone mass and bone strength to levels greater than those found in non-ovariectomized control rats. Taken together, these preclinical results establish sclerostin's role as a pivotal negative regulator of bone formation in the aging skeleton and, furthermore, suggest that antibody-mediated inhibition of sclerostin represents a promising new therapeutic approach for the anabolic treatment of bone-related disorders, such as postmenopausal osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S., & Kasai, S. (1983) · The Journal of cell biology · doi:10.1083/jcb.96.1.191 · Cited by 1,671
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Self-citationThe ovariectomized rat model of postmenopausal bone loss
Kalu, D. N. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90124-i · Cited by 1,361
Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors
Gordon, M. D., & Nusse, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600015200 · Cited by 1,333
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Self-citationvan Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Boutroy, S., Van Rietbergen, B., Sornay-Rendu, E., Munoz, F., Bouxsein, M. L., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071108 · Cited by 470
Candidates for the Mechanosensory System in Bone
Cowin, S. C., Moss-Salentijn, L., & Moss, M. L. (1991) · Journal of Biomechanical Engineering · doi:10.1115/1.2891234 · Cited by 468
On the rat model of human osteopenias and osteoporoses
Frost, H. M., & Jee, W. S. S. (1992) · Bone and Mineral · doi:10.1016/0169-6009(92)90809-r · Cited by 460
Osteocytes, strain detection, bone modeling and remodeling
Lanyon, L. E. (1993) · Calcified Tissue International · doi:10.1007/bf01673415 · Cited by 435
Ellies, D. L., Viviano, B., McCarthy, J., Rey, J.-P., Itasaki, N., Saunders, S., & Krumlauf, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060810 · Cited by 350
Toward a unifying theory of bone remodeling
Martin, R. B. (2000) · Bone · doi:10.1016/s8756-3282(99)00241-0 · Cited by 335
van Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H., Vrieling, H., Papapoulos, S. E., ten Dijke, P., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061002 · Cited by 283
Regional differences in cortical porosity in the fractured femoral neck
Bell, K. L., Loveridge, N., Power, J., Garrahan, N., Meggitt, B. F., & Reeve, J. (1999) · Bone · doi:10.1016/s8756-3282(98)00143-4 · Cited by 264
Turner, R. T., Wakley, G. K., & Hannon, K. S. (1990) · Journal of Orthopaedic Research · doi:10.1002/jor.1100080418 · Cited by 238
The natural history of sclerosteosis
Hamersma, H., Gardner, J., & Beighton, P. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00036.x · Cited by 231
LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST
Semenov, M. V., & He, X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609509200 · Cited by 222
Wachter, N. J., Krischak, G. D., Mentzel, M., Sarkar, M. R., Ebinger, T., Kinzl, L., Claes, L., & Augat, P. (2002) · Bone · doi:10.1016/s8756-3282(02)00779-2 · Cited by 203
The structure of bone tissues and the cellular control of their deposition.
Marotti, G. (1996) · PubMed · Cited by 186
Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140
Self-citationUpdate in Osteoporosis and Metabolic Bone Disorders
Shoback, D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0042 · Cited by 113
Glucocorticoids Inhibit Developmental Stage-specific Osteoblast Cell Cycle
Smith, E., Redman, R. A., Logg, C. R., Coetzee, G. A., Kasahara, N., & Frenkel, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001758200 · Cited by 113
Gasser, J. A., Ingold, P., Venturiere, A., Shen, V., & Green, J. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071207 · Cited by 107
Mosekilde, L., Danielsen, C. C., Søgaard, C. H., McOsker, J. E., & Wronski, T. J. (1995) · Bone · doi:10.1016/8756-3282(94)00033-v · Cited by 105
Sato, M., McClintock, C., Kim, J., Turner, C. H., Bryant, H. U., Magee, D. E., & Slemenda, C. W. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090517 · Cited by 103
Stein, S. A., Witkop, C. J., Hill, S. C., Fallon, M. D., Viernstein, L. J., Gucer, G., McKeever, P. E., Long, D. M., Altman, J., Miller, N. R., et al. (1983) · Neurology · doi:10.1212/wnl.33.3.267 · Cited by 97
Li, M., Mosekilde, L., Søgaard, C. H., Thomsen, J. S., & Wronski, T. J. (1995) · Bone · doi:10.1016/8756-3282(95)00115-t · Cited by 89
Brouwers, J. E. M., Lambers, F. M., Gasser, J. A., van Rietbergen, B., & Huiskes, R. (2008) · Calcified Tissue International · doi:10.1007/s00223-007-9084-3 · Cited by 85
Beighton, P. (1988) · Journal of Medical Genetics · doi:10.1136/jmg.25.3.200 · Cited by 85
Sato, M., Bryant, H. U., Iversen, P. W., Helterbrand, J., Smietana, F. R., Bemis, K. G., Higgs, R. E., Turner, C. H., Owan, I., Takano, Y., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20968-5 · Cited by 69
Osteon Morphometry in Females With Femoral Neck Fractures
Barth, R. W., Williams, J. L., & Kaplan, F. S. (1992) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199210000-00025 · Cited by 59
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Metadata
- Authors
- Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., Chen, Q., Winters, A., Boone, T., Geng, Z., Niu, Q.-T., Ke, H. Z., Kostenuik, P. J., Simonet, W. S., Lacey, D. L., & Paszty, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-01
- Volume
- 24
- Issue
- 4
- Pages
- 578-588
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1983220846
- Cited by
- 784
- References
- 40
- FWCI
- 46.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.